Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This research reported that eflornithine HCl 13.9% cream generally has a favorable dermal safety profile for managing unwanted facial hair in women, though it can cause mild irritation under certain conditions.

This study found that topical niacinamide significantly improved the appearance of wrinkles, skin yellowing, and elasticity in aging facial skin over 12 weeks.

This study reports that long-term treatment with ritlecitinib is generally well tolerated for up to approximately five years in patients aged 12 and older with alopecia areata, with the safety profile aligning with previous data from the ALLEGRO clinical trials.

This study found that electronically-operated pneumatic injections for administering a peptide-hyaluronic acid combination were well tolerated and led to significant improvement in hair density and thickness for men with androgenic alopecia over six months, though the exact mechanism remains uncertain.

This study suggests that the dipeptide Pro-Ile has FGF18-like activity, can penetrate model human epidermis, and may have potential as a cosmetic ingredient for skin and hair regulation.

This study found that the endolaser technique using a small incision is as effective as standard forehead lifts for reducing glabellar frown lines and forehead creases with a shorter recovery time.

This animal study found that transparent porcine-derived Type I atelocollagen increases skin thickness and regenerates elastic fibers in aged mice, suggesting its potential as a skin booster for rejuvenation.

This study found that engineered high-affinity soluble CD200R agonists, including ARQ-234, showed superior efficacy in reducing immune responses in various preclinical models of inflammatory conditions, suggesting potential as a therapeutic for atopic dermatitis and other related diseases.

In this study, the use of Endolift laser treatment significantly improved upper eyelid laxity and eyebrow height in nine patients, with evaluations conducted by blinded physicians showing notable cosmetic outcomes 6 months post-treatment.

This study found that torilin from Torilis japonica fruit extract inhibited 5 alpha-reductase in vitro more effectively than alpha-linolenic acid but less effectively than finasteride.

In this study, topical applications of Agrimonia pilosa extract and agrimonolide demonstrated notable anti-inflammatory and wound healing benefits in animal models, significantly reducing inflammation and enhancing wound closure compared to controls. However, further research in humans is needed to confirm these preclinical findings.

This article discusses the urgent issue of preserving freedom of choice in dermatology, highlighted by the American Academy of Dermatology, and reports no new research findings.

In this study using a virtual screening approach, eriocitrin and silymarin were identified as potent flavonoid compounds that strongly and stably interacted with 5α-reductase type II, suggesting potential development as novel treatments for androgenic alopecia.

This review highlights concerns about dermatological side effects linked to rapid weight loss from glucagon-like peptide-1 receptor agonists used for type 2 diabetes and obesity treatment, such as skin laxity, decreased collagen, and hair loss, emphasizing the importance of managing these while retaining metabolic benefits.

The medicine Diane is effective in treating hair loss, severe acne, and excessive hair growth.

In this study, ritlecitinib showed sustained effectiveness and a favorable safety profile in treating alopecia areata in patients aged 12 and older over 24 months, with improvements observed in hair and eyebrow regrowth and patient satisfaction.

In this study, a single platelet-rich plasma injection for facial rejuvenation improved patient satisfaction and skin elasticity, with the most notable effects occurring 1-2 weeks post-treatment.

This study found that subcutaneous injections of guanethidine or 6-hydroxydopamine induced premature hair growth in mice, suggesting a role for sympathetic nerves in hair growth control.

This article reviews the latest data on non-invasive body rejuvenation techniques, discussing advancements in filler technology and offering insights into their effectiveness and safety for both practitioners and patients interested in non-surgical procedures.

Hydrogel microneedles with special nanoparticles and growth factor improve hair growth better than minoxidil for hair loss treatment.

This study found that RXR and RAR proteins were detectable in normal human skin, suggesting they may play a role in epidermal cell differentiation and hair and gland physiology.

RV3466F lotion significantly reduces hair loss and improves acute telogen effluvium.

In this exploratory randomized controlled trial, participants using a combination of Centella asiatica-derived extracellular vesicles with recombinant growth factors showed significant improvements in hair thickness, density, length, and reduced hair loss and scalp sebum content after 56 days, compared to placebo.

This study suggests that combining GliSODin(®) Skin Nutrients with tazarotene cream significantly benefits facial fine wrinkles, photodamage, moisture, and elasticity compared to tazarotene alone.

INTASYL is a promising, adaptable RNAi technology for treating skin cancers.

In this study, retinoic acid treatments induced glandular and feather formation in embryos by altering positional values and activating specific retinoic acid nuclear receptor gene expression.

In this study, researchers developed a three-dimensional ultrastructural analysis tool using serial block-face scanning electron microscopy to reveal detailed nerve networks and muscle structures in human skin tissues, demonstrating the technique's potential to study structural changes in aging or disease.

This review summarizes the anatomy and physiology of the arrector pili muscle and discusses its potential role in hair loss disorders, reporting no new clinical results.

This review analyzes the mechanism and evidence supporting the approved use of ritlecitinib, a JAK3/TEC kinase inhibitor, for treating severe alopecia areata in patients aged 12 and older, highlighting its role in the changing therapeutic landscape of this immune-mediated disease.